SCHEMBL3336140

SCHEMBL3336140

CCCN(CCC)CCc1cccc(-c2c(OC)cccc2OC)c1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 3/20 0.72
HTR1A P08908 2/20 0.72
SIGMAR1 Q99720 2/20 0.54
EBP Q15125 1/20 0.54
TMEM97 Q5BJF2 1/20 0.54
HTR1D P28221 1/20 0.54
HTR1B P28222 1/20 0.54
HTR2A P28223 1/20 0.54
HTR2B P41595 1/20 0.54
HTR5A P47898 1/20 0.54
DRD2 P14416 2/20 0.54
DRD3 P35462 2/20 0.54
DRD1 P21728 1/20 0.54
DRD4 P21917 1/20 0.54
DRD5 P21918 1/20 0.54
OPRM1 P35372 1/20 0.50
OPRD1 P41143 1/20 0.50
OPRK1 P41145 1/20 0.50
BCHE P06276 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341529 0.90 HTR7 (0.74) HTR7HTR1ASIGMAR1EBPTMEM97
SCHEMBL3337267 0.86 HTR7 (0.73) HTR7HTR1ASIGMAR1EBPTMEM97
SCHEMBL3336197 0.84 HTR7 (1.00) HTR7HTR1AHTR1DHTR1BHTR2A
SCHEMBL3338076 0.81 HTR7 (0.69) HTR7HTR1ADRD2DRD3DRD1
SCHEMBL4679361 0.79 HTR7 (0.74) HTR7HTR1AHTR1DHTR1BHTR2A
SCHEMBL3338744 0.77 HTR7 (0.68) HTR7HTR1AHTR2AHTR2B
SCHEMBL11655881 0.77 AOC3 (0.64) SIGMAR1EBPTMEM97DRD2DRD3
SCHEMBL3340335 0.76 HTR7 (0.75) HTR7HTR1AHTR1DHTR1BHTR2A
SCHEMBL11517042 0.75 SIGMAR1 (0.82) SIGMAR1EBPTMEM97HTR2AHTR2B
SCHEMBL10959196 0.75 SIGMAR1 (0.70) SIGMAR1EBPTMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2676954-A1 Heterocyclyl-substituted-phenyl derivatives as vasodilators Laboratorios del Dr. Esteve S.A. (ES) 2013-12-25 EP claimed
US-20100152252-A1 Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE,S.A. (ES) 2010-06-17 US claimed
EP-1997807-A1 Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments Laboratorios del Dr. Esteve S.A. (ES) 2008-12-03 EP claimed
EP-1935886-A1 Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments Laboratorios del Dr. Esteve S.A. (ES) 2008-06-25 EP claimed
EP-2676954-A1 Heterocyclyl-substituted-phenyl derivatives as vasodilators Laboratorios del Dr. Esteve S.A. (ES) 2013-12-25 EP disclosed
US-20100197717-A1 COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2010-08-05 US disclosed
US-20100197717-A1 COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2010-08-05 US disclosed
US-20100152252-A1 Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE,S.A. (ES) 2010-06-17 US disclosed
US-20100152252-A1 Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE,S.A. (ES) 2010-06-17 US disclosed
US-20100152252-A1 Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE,S.A. (ES) 2010-06-17 US disclosed
EP-2114894-A1 HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-11-11 EP disclosed
EP-1997493-A1 Combination of a 5-HT7 receptor ligand and an opioid receptor ligand Laboratorios del Dr. Esteve S.A. (ES) 2008-12-03 EP disclosed
EP-1997493-A1 Combination of a 5-HT7 receptor ligand and an opioid receptor ligand Laboratorios del Dr. Esteve S.A. (ES) 2008-12-03 EP disclosed
EP-1997807-A1 Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments Laboratorios del Dr. Esteve S.A. (ES) 2008-12-03 EP disclosed
WO-2008077625-A1 HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-07-03 WO disclosed
EP-1935886-A1 Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments Laboratorios del Dr. Esteve S.A. (ES) 2008-06-25 EP disclosed
EP-1935886-A1 Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments Laboratorios del Dr. Esteve S.A. (ES) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197717-A1 COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND OPRL1, OPRM1, OPRK1 HTR7 5/4885HTR1A 8/4885SIGMAR1 19/4885
US-20100152252-A1 Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments PKM, PKLR, HNMT HTR7 630/4885HTR1A 1355/4885SIGMAR1 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.